401 Avsnitt

  1. Episode 323 ASCO24: TDXD in Bladder Cancer

    Publicerades: 2024-06-02

  2. Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)

    Publicerades: 2024-06-02

  3. Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?

    Publicerades: 2024-06-01

  4. Episode 320: Team Canada's entry for the Uromigos Cup

    Publicerades: 2024-05-25

  5. Episode 319: ASCO 2024: A Preview of GU Data

    Publicerades: 2024-05-19

  6. Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases

    Publicerades: 2024-05-13

  7. Episode 317: AUA 2024 Preview with the AUA Secretary

    Publicerades: 2024-05-01

  8. Episode 316: APCCC 2024 Summary with Silke Gillessen

    Publicerades: 2024-04-28

  9. Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer

    Publicerades: 2024-04-27

  10. Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer

    Publicerades: 2024-04-27

  11. Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease

    Publicerades: 2024-04-26

  12. Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer

    Publicerades: 2024-04-26

  13. Episode 311: The Uromigos Paper of the Month - The POUT Trial

    Publicerades: 2024-04-23

  14. Episode 310: Dosing and duration of drugs from a cost perspective

    Publicerades: 2024-04-17

  15. Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer

    Publicerades: 2024-04-07

  16. Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy

    Publicerades: 2024-04-07

  17. Episode 307: Bladder-Sparing Approaches Part 2

    Publicerades: 2024-04-02

  18. Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC

    Publicerades: 2024-03-28

  19. Episode 305: FDA and Oncology Clinical Trials

    Publicerades: 2024-03-19

  20. Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC

    Publicerades: 2024-03-11

5 / 21

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Visit the podcast's native language site